Cargando…

Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis

OBJECTIVES: The study aims to summarize publication characteristics of anti-programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immunotherapy for esophageal cancer and create scientific maps to explore hotspots and emerging trends with bibliometric methods. METHODS: The p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yuanyuan, Wang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714501/
https://www.ncbi.nlm.nih.gov/pubmed/36465399
http://dx.doi.org/10.3389/fonc.2022.983892
_version_ 1784842241872756736
author Yang, Yuanyuan
Wang, Feng
author_facet Yang, Yuanyuan
Wang, Feng
author_sort Yang, Yuanyuan
collection PubMed
description OBJECTIVES: The study aims to summarize publication characteristics of anti-programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immunotherapy for esophageal cancer and create scientific maps to explore hotspots and emerging trends with bibliometric methods. METHODS: The publications between 2012 and 2021 were retrieved from the Web of Science Core Collection (WoSCC) on June 20, 2022. Bibliometric tools including HistCite, VOSviewer, and CiteSpace were used for statistical analysis. Data on the trend of the annual output, countries/regions, institutions, journals, authors, subject categories, keywords, and co-cited references were presented in this study. RESULTS: A total of 552 publications written by 3,623 authors of 872 institutions, 44 countries/regions in 250 journals were included in the bibliometric study. China, USA and Japan were the key countries in this field. Kato Ken, Bang Yung-Jue, Frontiers in Oncology, Journal of Clinical Oncology and Natl Canc Ctr were the top 1 productive author, co-cited author, productive journal, co-cited journal and prolific institution, respectively. The top 4 most present keywords were esophageal cancer, immunotherapy, esophageal squamous cell carcinoma and PD-L1. Neoadjuvant chemotherapy, response, PD-1 blockade and CD8(+) T cell were four latest research frontiers. The keywords reflected the progress from PD-1/PD-L1 expression to the clinical application of PD-1/PD-L1 inhibitors. The current researches mainly focus on neoadjuvant immunotherapy for esophageal cancer and development of biomarkers. Further research is warranted to determine effective predictive biomarkers or models, illustrate the molecular mechanism of combined treatment, and construct the optimal therapeutic strategy. CONCLUSIONS: This study visually analyzed the global trend and hotspots of anti-PD-1/PD-L1 immunotherapy for esophageal cancer over the past decade. The results could guide scientists to comprehensively understand the global frontiers and determine future directions.
format Online
Article
Text
id pubmed-9714501
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97145012022-12-02 Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis Yang, Yuanyuan Wang, Feng Front Oncol Oncology OBJECTIVES: The study aims to summarize publication characteristics of anti-programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immunotherapy for esophageal cancer and create scientific maps to explore hotspots and emerging trends with bibliometric methods. METHODS: The publications between 2012 and 2021 were retrieved from the Web of Science Core Collection (WoSCC) on June 20, 2022. Bibliometric tools including HistCite, VOSviewer, and CiteSpace were used for statistical analysis. Data on the trend of the annual output, countries/regions, institutions, journals, authors, subject categories, keywords, and co-cited references were presented in this study. RESULTS: A total of 552 publications written by 3,623 authors of 872 institutions, 44 countries/regions in 250 journals were included in the bibliometric study. China, USA and Japan were the key countries in this field. Kato Ken, Bang Yung-Jue, Frontiers in Oncology, Journal of Clinical Oncology and Natl Canc Ctr were the top 1 productive author, co-cited author, productive journal, co-cited journal and prolific institution, respectively. The top 4 most present keywords were esophageal cancer, immunotherapy, esophageal squamous cell carcinoma and PD-L1. Neoadjuvant chemotherapy, response, PD-1 blockade and CD8(+) T cell were four latest research frontiers. The keywords reflected the progress from PD-1/PD-L1 expression to the clinical application of PD-1/PD-L1 inhibitors. The current researches mainly focus on neoadjuvant immunotherapy for esophageal cancer and development of biomarkers. Further research is warranted to determine effective predictive biomarkers or models, illustrate the molecular mechanism of combined treatment, and construct the optimal therapeutic strategy. CONCLUSIONS: This study visually analyzed the global trend and hotspots of anti-PD-1/PD-L1 immunotherapy for esophageal cancer over the past decade. The results could guide scientists to comprehensively understand the global frontiers and determine future directions. Frontiers Media S.A. 2022-11-17 /pmc/articles/PMC9714501/ /pubmed/36465399 http://dx.doi.org/10.3389/fonc.2022.983892 Text en Copyright © 2022 Yang and Wang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Yuanyuan
Wang, Feng
Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
title Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
title_full Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
title_fullStr Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
title_full_unstemmed Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
title_short Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis
title_sort research trends on anti-pd-1/pd-l1 immunotherapy for esophageal cancer: a bibliometric analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714501/
https://www.ncbi.nlm.nih.gov/pubmed/36465399
http://dx.doi.org/10.3389/fonc.2022.983892
work_keys_str_mv AT yangyuanyuan researchtrendsonantipd1pdl1immunotherapyforesophagealcancerabibliometricanalysis
AT wangfeng researchtrendsonantipd1pdl1immunotherapyforesophagealcancerabibliometricanalysis